Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (96)	5/21/1998 3:34:00 PM
From: Bruce Galpeer	Read Replies (1) \| Respond to of 4891

Post #66 This was the story on PRN this morning. exchange2000.com

To: BARRY ALLEN who wrote (96)	5/21/1998 3:46:00 PM
From: JustMy2Cents	Respond to of 4891

Thanks Barry

To: BARRY ALLEN who wrote (96)	5/21/1998 5:19:00 PM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 4891

13:10 DJ Advanced Viral Drug Stimulates Immune Sys In HIV Patients ATLANTA (Dow Jones)--Advanced Viral Research Corp. (ADVR) said Phase III clinical trials of Reticulose showed the drug stimulated immune system response in adult HIV patients. Reticulose is a non-toxic, peptide-nucleic acid that stimulates the cytocidal arm of the immune system. In a press release Thursday, the company said that in the trial, Reticulose-treated patients showed early, sustained improvements in CD4 and CD8 cell counts, significant decreases in viral loads, significant weight gain, fewer opportunistic infections and lowered mortality, compared to patients receiving placebo. The company said none of the reticulose-treated patients developed severe orlife-threatening opportunistic infections. Advanced Viral Research said that in the double-blind, placebo-controlled trial, Reticulose or placebo was administered to 43 treatment-naive patients over the course of 60 days. The company said that at the end of treatment, the Reticulose patients averaged a 37% increase in their CD4 cell counts, while the patients in the placebo group experienced a 7% decline. Sixty days after cessation of treatment, the mean CD4 cell count of the Reticulose group was up 53%. At the end of treatment, there was also a 17% increase in the CD8 cell counts of patients in the Reticulose group, compared to a 2% increase in the placebo group. The company said body weight increased in 71% percent of the Reticulose patients, while 60% of the placebo patients lost weigh, and HIV viral loads decreased by at least 0.5 logs in four Reticulose treated patients, but in none of the placebo group. The clinical trials were conducted at the Queen Elizabeth Hospital of the University of the West Indies School of Medicine in Barbados. Advanced Viral Research is a biotechnology company specializing in the development of peptide nucleic acids for pharmaceutical use. (END) DOW JONES NEWS 05-21-98